Vaccine hesitancy in low- and middle-income countries: potential implications for the COVID-19 response
2020; BMJ; Volume: 106; Issue: 2 Linguagem: Inglês
10.1136/archdischild-2020-318988
ISSN1468-2044
Autores Tópico(s)COVID-19 epidemiological studies
ResumoAt this point in the COVID-19 pandemic, children are relatively spared by the direct effects of the SARS-CoV-2 virus, but their role in transmission is less understood. Conclusions on these issues call for caution, as the nature of the pandemic and the virus changes. Global health organisations and national governments are pinning hopes for a return to quasinormality on the development of a safe and effective vaccine that can be quickly manufactured and supplied around the world for use at scale in record time. There are currently more than 100 such vaccine candidates with phase 1, 2 and 3 studies in progress. Adults who are at high-risk of COVID-19 may overwhelmingly choose to receive a vaccine, but it remains unclear if an exclusively adult targeted vaccine campaign would be sufficient to interrupt transmission. Some experts estimate that, at a minimum, 60% population level immunity will be required.1 This figure rises if R increases. Particularly in low-income and middle-income countries (LMICs) with a high proportion of young people and less well-established adult vaccination programmes, widespread childhood vaccination may also be necessary. This leads us to consider the likely acceptability of a novel COVID-19 vaccination for children, who are—at this stage of the pandemic—mostly not severely affected by COVID-19. The good news is that vaccinations are largely accepted in LMICs. According to the results of the 2018 Wellcome Global Monitor, a survey of 140 000 individuals in …
Referência(s)